Cogent joins OnKure with a clinical-stage H1047Rm-specific PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
Kura will see more combo data, while a new contender from Sumitomo emerges.
Astra squares up to Merck's Curon deal, while Novartis and Galapagos face off in fast-manufactured Car-T.
Second-line NSCLC is a $1.8bn write-off, and Gilead plans phase 3 in SCLC.
The company abandons TNG908, but is still all in on the troubled target.
Reports of Arc-10's failure are greatly exaggerated, the company argues.
An ASH abstract reveals no delayed neurotoxicity, but three deaths, with anito-cel.
